Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 0.66 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | FGR | P09769 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | FER | P16591 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19441282 | 0.91 | SYK (0.63) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL18176976 | 0.85 | SYK (0.55) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2013492 | 0.83 | SYK (0.74) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2041879 | 0.82 | SYK (0.64) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16205213 | 0.81 | SYK (0.54) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2509171 | 0.81 | SYK (0.66) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2503950 | 0.81 | SYK (0.66) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2050035 | 0.80 | SYK (0.53) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL2507112 | 0.80 | SYK (1.00) | SYKJAK2NTRK1FYNFGR | |
| SCHEMBL16198508 | 0.79 | SYK (0.69) | SYKJAK2NTRK1FYNFGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783531-B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160311813-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2016-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311813-A1 | THIAZOLE-SUBSTITUTED AMINOHETEROARYLS AS SPLEEN TYROSINE KINASE INHIBITORS | SYK, TYRO3, BTK | SYK 1/4885JAK2 5/4885NTRK1 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.